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Idiopathic aplastic anemia (AA) is a common cause of acquired bone marrow failure. 
Although autoimmunity to hematopoietic progenitors is thought to be responsible for  
its pathogenesis, little is known about the molecular basis of this autoimmunity.  Here 
we show that a substantial proportion of AA patients harbors clonal hematopoiesis 
characterized by the presence of acquired copy number-neutral loss of heterozygosity 
(CNN-LOH) of the 6p arms (6pLOH).  The 6pLOH commonly involved the human 
leukocyte antigen (HLA) locus, leading to loss of one HLA haplotype.  Loss of 
HLA-A expression from multiple lineages of leukocytes was confirmed by flow 
cytometry in all 6pLOH(+) cases.  Surprisingly, the missing HLA-alleles in 
6pLOH(+) clones were conspicuously biased to particular alleles, including 
HLA-A*02:01, A*02:06, A*31:01, and B*40:02.  A large scale epidemiological 
study on the HLA alleles of patients with various hematologic diseases revealed that 
the four HLA alleles were overrepresented in the germline of AA patients.  These 
findings indicate that the 6pLOH(+) hematopoiesis found in AA represents „escape‟ 
hematopoiesis from the autoimmunity, which is mediated by cytotoxic T-cells that 
target the relevant auto-antigens presented on hematopoietic progenitors through these 
class I HLAs.  Our results provide a novel insight into the genetic basis of the 
pathogenesis of AA. 
 Introduction 
Acquired aplastic anemia (AA) is a rare condition associated with bone marrow failure 
and pancytopenia1.  A series of classical observations and experiments have 
unequivocally supported that the auto-immunity to hematopoietic stem / progenitor cells 
(HSPCs) critically underlies the pathogenesis of the bone marrow failure in the majority 
of AA cases.  According to the widely accepted model of immune-mediated bone 
marrow failure, activated cytotoxic T cells (CTLs) that recognize an auto-antigen(s) 
presented on HSPCs through their class I HLA molecules have a major role in initiating 
the autoimmune reactions2-4.  However, no definitive evidence exists that supports this 
model or the presence of such CTL repertoires.  Moreover, little information is 
available about their target antigens or about the way by which they are recognized by 
effector T cells. 
Another long-standing issue on AA is its close relationship with clonal 
hematopoiesis5,6.  It was first suspected from an apparent overlap between AA and 
paroxysmal nocturnal hemoglobinuria (PNH)7,8, and was also implicated by the 
frequent development of late clonal disorders in AA, such as myelodysplastic 
syndromes (MDS), PNH, or even acute myeloid leukemia (AML)9-11.  Clonal 
hematopoiesis can be explicitly demonstrated by conventional clonality assays at 
presentation in a substantial proportion of newly diagnosed typical AA cases12.  
Although it has been expected that the inciting autoimmune insult somehow confers 
selective pressures on the evolution of clonal hematopoiesis5, the exact mechanism for 
such immunological selection or escape is still unclear. 
The objectives of this study, therefore, were to characterize the clonal nature of the 
hematopoiesis that is maintained even under the severe autoimmune insult in AA, and 
 to explore the genetic/immunologic mechanism that could underlie the pathogenesis of 
AA.  To achieve these aims, we performed single nucleotide polymorphism (SNP) 
array-based analysis of genomic copy numbers and/or allelic imbalances in peripheral 
blood (PB) specimens obtained from 306 patients with AA.  Initially, we found that 
AA patients frequently showed clonal/oligoclonal hematopoiesis that lost specific HLA 
alleles as a result of copy number-neutral loss of heterozygosity (CNN-LOH) of the 6p 
arms, which led us to further analyses of the contribution of 6pLOH(+) clones to 
residual hematopoiesis and a large scale epidemiological study on the HLA alleles that 
are overrepresented in AA, involving a total of 6,613 transplants registered in the Japan 





PB specimens from a total of 306 patients with AA were analyzed for the presence of 
genetic alterations using SNP arrays (see below).  The clinical characteristics of these 
patients are summarized in Table 1 and Supplementary Table 1.  Among the 306 
patients, 107 were newly diagnosed while 199 were previously treated.  Ninety-six 
patients received allogeneic bone marrow transplantation from unrelated donors 
through the JMDP, and their HLA information was available from the JMDP.  The 
other 210 were newly genotyped for HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 
alleles as described elsewhere13.  103 patients had been treated with anti-thymocyte 
globulin (ATG) plus cyclosporine (CsA), CsA alone, or anabolic steroids at the time of 
sampling.  All patients and healthy individuals provided their informed consent before 
 sampling.  The study protocol was approved by the ethics committee of the Graduate 
School of Medical Science, Kanazawa University and also by that of the Graduate 
School of Medicine, University of Tokyo. 
 
Analysis of genomic copy numbers and detection of 6pLOH 
Genomic copy numbers, as well as allele-specific copy numbers, were analyzed by 
using GeneChip® 500K arrays (Affymetrix) as previously described14,15.  Briefly, 
genomic DNA from AA patients and normal controls were analyzed on GeneChip® 
500K arrays separately.  After adjusting several biases introduced during experiments, 
signal ratios of the corresponding probes between test (patient) and controls were 
calculated across the genome to obtain genome-wide copy numbers.  Genetic lesions, 
including copy number gains and losses, as well as CNN-LOHs, were first detected 
using a hidden Markov model (HMM)-based algorithm implemented in the CNAG 
software14,15.  Known copy number variations were carefully excluded by referring to 
the Database of Genomic Variants (http://projects.tcag.ca/variation/).  CNN-LOH in 
6p involving the HLA locus was more specifically and sensitively detected by 
statistically evaluating the mean differences in allele-specific copy numbers between 
heterozygous SNPs on 6p (N=~1,400) that were telomeric from the 5‟ end of the 
HLA-A locus (rs1655927) and all non-6p heterozygous SNPs (N=~10,5000) using the 
Mann-Whitney's U test with the R package (http://www.r-project.org/).  Possible false 
positive findings arising from multiple testing involving the 306 samples were 
evaluated by maintaining the false discovery rate (FDR) under 0.01 as previously 
described16, where the microarray data of 1,000 JMDP donor specimens obtained from 
 an ongoing whole genome association study (unpublished data) were used to calculate 
an empiric null distribution17,18. 
 
Determination of the missing HLA alleles in 6pLOH(+) clones in patients with AA 
The 500K SNP data of the 1,800 JMDP donor-recipient pairs (JMDP data set), together 
with their HLA genotyping information, was used to generate an HLA SNP haplotype 
table on the GeneChip® 500K platform, which contains the consensus SNPs of the 
three major haplotypes (P1, P2, and P3) in Japanese subjects
18
 and the SNP sequences 
of all observed HLA haplotypes complementary to either of P1-P3 within the JMDP set 
(N = 1576) (data not shown).  To determine the missing HLA haplotype in each 
6pLOH(+) patient, those “HLA” haplotypes were first selected from the above HLA 
haplotype table that were compatible with the observed HLA genotypes of that patient.  
Among these, a candidate haplotype was selected such that it contained the minimum 
number of SNPs that were incompatible with the patient‟s genotype.  For each 
candidate haplotype, genomic copy numbers were inferred at the heterozygous SNPs 
along that haplotype using the circular binary segmentation algorithm
19,20
, which 
divided the haplotype into one or more discrete segments with different mean copy 
numbers.  Finally, each copy number segment was thought to be „missing‟, when the 
alternative hypothesis 

Ha:Si Si, for 
i  was supported against the null hypothesis 

H0 :Si Si, for 
i  using the Wilcoxon signed rank test with a significance level of 
0.05, where 

Si  represents the allele-specific copy number at the ith heterozygous SNP 
site within the segment of the candidate haplotype with 

Si  being the corresponding 
value for the complementary haplotype (Supplementary Figure. 1).  Finally, for those 
 HLA types that appeared more than 8 times among 6pLOH(+) cases, their contribution 
to the observed allelic loss of HLA haplotypes was evaluated by multi-variate logistic 
regression analysis with stepwise backward selection 
 
Flow cytometry 
Heparinized PB and BM were collected from the patients at diagnosis and/or after 
treatment.  HLA-A expression on granulocytes, monocytes, B and T cells, and BM 
CD34+ cells was analyzed by flow cytometry using a FACS Canto II® instrument 
(Beckton Dickinson) with the FlowJo program (Tree Star, Inc.).  The monoclonal 
antibodies used for this study are provided in Supplementary Table 2. 
 
Human Androgen Receptor Assay (HUMARA) 
The human androgen receptor gene was amplified from genomic DNA of 23 female 
patients including 3 6pLOH(+) patients, as described by Ishiyama et al.
21
 with some 
modifications.  Clonality was assessed using an “S value” as a marker of skewing in 
granulocytes and T lymphocytes.  
 
Association of HLA types with AA 
A total of 6,613 patients who had received allogeneic bone marrow transplantation 
through the JMDP between 1992 and 2008 were investigated to see whether the HLA 
alleles frequently missing in CNN-LOH in 6p with the development of AA could 
represent risk alleles for the development of AA.  Thus, the frequencies of patients 
with each of the candidate risk alleles (HLA-A*31:01, B*40:02, A*02:01 and A*02:06) 
and those having none of these alleles were compared between 407 patients with AA 
 and those with other hematopoietic disorders (1,827 with AML, 1,606 with acute 
lymphocytic leukemia, 1,014 with chronic myeloid leukemia, 825 with MDS, 566 with 
non-Hodgkin lymphoma, and 368 with other hematopoietic neoplasms) 





Genetic lesions in AA detected by SNP array analysis 
After excluding known or suspected copy number variations, a total of 50 genetic 
lesions were identified in 46 out of the 306 (15%) PB specimens of our AA case series 
(Table 1 and Figure. 1).  Among these by far the most conspicuous was the recurrent 
CNN-LOH involving the 6p arm, which was detected in 28 cases as a significant 
dissociation of allele-specific copy number graphs in 6p regions using a hidden Markov 
model (HMM)-based algorithm implemented in the CNAG software2,14,15 (Figure. 2A 
and 2B).  Of particular interest was that all CNN-LOH in 6p commonly affected the 
HLA locus, causing a haploid loss of HLA alleles and uniparental HLA expression.  In 
some cases, the breakpoint of the 6pLOH was predicted to fall within the HLA locus 
(Figure. 2B).  These findings strongly indicated that the HLA locus was the genetic 
target of these 6pLOHs.  Also supporting this was the finding that in half of the cases, 
the dissociations in the allele-specific copy number graphs were gradually attenuated to 
the baseline over several mega base pair regions rather than showing a discrete 
breakpoint, indicating the presence of multiple 6pLOH(+) clones within a single case 
that had different breakpoints but still shared the same missing HLA alleles (Figure. 
 2C).  Moreover, the 6pUPDs existing only in a minor population were more 
sensitively detected by statistically evaluating the size of dissociation of allele-specific 
copy numbers in the 6p arm.  With this improved statistical test, CNN-LOH in 6p was 
found in a total of 40 cases (13%) (Figure. 2D and Supplementary Figure. 2), where the 
FDR was maintained at 0.01 to avoid too many false positive findings.  In all 
6pLOH(+) cases, substantial numbers of heterozygous SNP calls were retained within 
the affected regions, thus indicating that the CNN-LOHs in 6p were not constitutional 
but represented acquired genetic events only found in the affected subclones (Figure. 1).  
In fact, all 6pLOH(+) cases were shown to have „heterozygous‟ HLA alleles in 
high-resolution HLA typing of their PB (Table 2).  Moreover, 6pLOH was not 
detected in the CD3-positive T cells in selected cases (cases 25 and 26, Supplementary 
Figure. 3).  By quantitatively comparing the observed differences in allele-specific 
copy numbers in the 6pLOH segments with what were expected assuming 100% 
LOH(+) components, the 6pLOH(+) clones were estimated to account for 0.2 % to 
53.9 % of the PB leukocytes (Table 2).  The trend of the lower percentages of the 
6pLOH(+) fraction in newly diagnosed patients compared to those in patients at 
remission was thought to reflect the fact that the former patients tended to have lower 
counts of granulocytes and monocytes, which were the predominant targets of 6pLOH 
(see below).   
The disease status of the 40 patients at the sampling was before treatment in 16 cases, 
during remission for 1-16 years after therapies in 15, and before bone marrow 
transplantation for refractory disease in 9.  All evaluable 6pLOH(+) AA cases 
responded to immunosuppressive therapy (IST) (23/23), whereas 101 of 126 evaluable 
cases with 6pLOH(−) responded (P = 0.014) (Table 3). 
  
Uniparental expression of HLA-A in multi-lineage hematopoietic cells 
The genetic loss of one HLA haplotype in SNP array analysis was further confirmed by 
expression analysis of HLA-A in PB leukocytes using flow cytometry in 19 eligible 
cases with 6pLOH(+), in which the HLA-A alleles were heterozygous and fresh PB 
samples were available.  Loss of expression of one HLA-A antigen was confirmed in 
all 19 6pLOH(+) cases (Figure. 3A and Supplementary Figure. 4).  The HLA-A 
missing cells in the PB were shown to have appeared shortly after the onset or before 
the initiation of treatments in 2 cases, and were confirmed to persist for 1 – 16 (median 
6) months in 14 patients (Supplementary Table 1 and Supplementary Figure. 5).  The 
percentage of granulocytes lacking HLA-A antigens in the 2 patients who were 
responsive to IST remained almost the same during the convalescent period of 2-3 
months (Supplementary Figure. 6).  Importantly, uniparental expression of HLA-A 
alleles was detected in multiple cell lineages, including granulocytes, monocytes, B 
cells, and to a lesser extent, in T cells.  Moreover, uniparental HLA-A expression was 
demonstrated in bone marrow (BM) CD34+ cells in 5 patients whose BM samples were 
available for flow cytometry.  All 5 patients possessed varying proportions of BM 
CD34+ cells (49.7 to 71.3%), which had lost the expression of one HLA-A antigen, and 
in each case, the missing HLA-A allele was identical to that in the PB leukocytes 
(Figure. 3B).  The uniparental expression of HLA-A in case 13 was also observed in 
the CD34+ compartment of the archived BM specimen obtained 2 years before analysis 
(Supplementary Figure. 7).  Together, these findings suggested that the 6pLOH 
involved early HSPCs, and that the 6pLOH occurred at the level of long-term 
repopulating stem cells.  
  
Clonality of the HLA-missing granulocytes 
The HUMARA (Human Androgen Receptor)-based clonality assays in granulocytes 
were performed in 3 6pLOH(+) and 20 6pLOH(−) patients, in which all three 
6pLOH(+) and 4 (20%) of the 6pLOH(−) patients showed evidence of clonality in 
granulocyte populations (Supplementary Figure. 8). 
 
Missing HLA alleles in 6pLOH 
Given that the HLA is the genetic target of 6pLOH in AA, the missing HLA alleles in 
6pLOH are of particular interest, because in this context, they are thought to be directly 
involved in the presentation of the target auto-antigens to CTLs, and therefore, to be 
critically important in the pathogenesis of AA.  We determined the missing HLA 
alleles in each 6pLOH(+) AA patient by the haplotype imputation of HLA alleles based 
on the large data of HLA haplotypes observed in the JMDP set, followed by statistical 
evaluation of allele-specific copy numbers along the imputed haplotypes (Figure. 4).  
The imputed haplotypes were confirmed in 4 cases by the family studies on the HLA.  
The allelic status was imputed at least partially in 39 out of the 40 6pLOH(+) cases.  
The imputed results were consistent with the patterns of uniparental expression of 
HLA-A in flow cytometry in 18 cases with 6pLOH (Table 2) (for details, see Figure. 4) 
except for those in case 26, in which no valid SNP haplotype around the HLA-A locus 
was identified and the status of HLA-A was determined by flow cytometry.  The 
missing HLA alleles in 6pLOH(+) AA showed a conspicuous deviation to some 
selected HLA alleles, including HLA-A*31:01, B*40:02, C*03:04, and to a lesser 
extent HLA-A*02:01 and A*02:06.  After the effects of linkage disequilibrium 
 between individual HLA alleles were taken into consideration by multi-variate analysis, 
4 HLA alleles were shown to remain as the principal determinants of the missing 
haplotypes, HLA-A*31:01, B*40:02, A*02:01 and A*02:06 (Supplementary Table 4). 
 
Overrepresentation of frequently missing HLAs in AA populations 
Because these missing HLA alleles in 6pLOH could be involved in the pathogenesis of 
AA, we next tested whether these relevant HLA alleles are associated with the risk of 
the development of AA among the 6,613 JMDP registrants.  As shown in Table 4, the 
4 major missing HLA alleles, HLA-A*31:01, B*40:02, A*02:01 and A*02:06 were 
more frequently observed in AA cases compared to non-significant HLA alleles (i.e. all 
HLA alleles other than these 4 alleles), where the odds ratios for the risk of the 
development of AA between each of these alleles and non-significant alleles were 1.87 
(95%CI; 1.43 - 2.43) for A*02:01, 2.22 (95%CI; 1.70 - 2.90) for A*02:06, 1.37 
(95%CI; 1.00 - 1.88) for A*31:01, and 1.95 (1.48 - 2.58) for B*40:02 (Table 4).  The 




The origin of clonal hematopoiesis in AA is a focus of long-standing disputes, in which 
a profoundly reduced hematopoietic stem cell pool and/or escape from the autoimmune 
insults have been implicated in the evolution of the clonal hematopoiesis in AA5,22,23.  
Our findings on 6pLOH in AA provide an intriguing insight not only into the 
underlying mechanism of the clonal hematopoiesis in AA, but also into the origin of the 
autoimmunity that is responsible for the pathogenesis of AA.  A recent study from the 
 United States also reported three cases with 6pLOH
24
.  With a sensitive detection 
algorithm, the presence of the 6pLOH(+) components was demonstrated in as many as 
13% of typical cases with AA, and the evidence from the subsequent studies strongly 
indicated that the HLA genes are the genetic targets of 6pLOH in AA patients.  First, 
the HLA locus was commonly and critically involved in all 6pLOHs found in AA.  
Second, some AA patients carried multiple 6pLOH(+) subclones with different 
breakpoints, but in all cases, the 6pLOH involved the HLA locus and occurred in a 
manner that targeted the same parental HLA allele.  Moreover, particular class I HLA 
alleles were overrepresented among 6pLOH(+) cases and consistently found in the 
missing haplotypes.  Finally, many of these HLA alleles were shown to be tightly 
associated with the development of AA in Japanese patients in case-control studies 
using the large JMDP registry. 
The conspicuous bias of the missing HLA alleles in 6pLOH to particular HLA types, 
and the significant association of AA with those HLA types strongly suggest that the 
recurrent 6pLOH in AA is a phenomenon tightly related to the pathogenesis of AA 
rather than mere secondary event during the course of AA.  Based on these 
observations, it is well reasoned that in 6pLOH(+) AA cases, the auto-immunity to 
HSPCs is mediated by the CTLs that target the antigens presented via specific class I 
HLA molecules, and that the 6pLOH(+) cells found in AA could be explained as 
escape hematopoiesis that survives the auto-immune insult by genetically deleting the 
relevant HLA species that are required for antigen presentation (Figure. 5).  These 
scenarios are further supported by the recent reports showing that the CNN-LOH in 6p 
provides a common mechanism of leukemic relapse after HLA haplo-identical stem 
cell transplantations, in which leukemic cells that lost the mismatched HLA haplotype 
 through CNN-LOH in 6p are thought to escape the immunological surveillance of the 
engrafted donor-T cells
25,26
.  Importantly, it was experimentally demonstrated by 
immunological assays that the 6pLOH(+) leukemic cells actually escaped GVL by 
CTLs, while 6pLOH(−) leukemic cells were effectively killed by the same CTLs.  
Although the immunological targets of CTLs are different between relapse after 
haplo-identical transplants (mismatched HLAs themselves) and AA (still unknown 
autoantigens presented on missing HLAs), the prominent similarities found in both 
cases further supports that CNN-LOH in 6p confers an escape mechanism from 
auto-reactive CTLs in AA. 
In light of the above considerations, the chronological behavior of the 6pLOH(+) 
components in PB is also interesting and worth discussing.  Despite the assumption 
that 6pLOH is an effective escape mechanism from CTLs, the 6pLOH(+) stem cells 
were unable to repopulate the BM to cure AA, unless effective IST was applied 
(Supplementary Figure. 6).  This is most likely explained by the presence of 
inflammatory cytokines, such as IFN-γ and TNF-α, which have also been shown to play 
an important role in the bone marrow failure in AA, and are thought to be responsible 
for the continued prevention of the 6pLOH(+) stem cells from fully expanding and 
reconstituting the BM (Supplementary Figure. 9A and 9B)
27,28
. 
When the autoimmune insults are removed after IST, no further injury of normal 
stem cells would occur.  However, this does not necessarily mean the surviving 
normal stem cells can eventually outnumber the 6pLOH(+) stem cells over time.  Note 
that once the autoimmune insults disappear, nothing could biologically or 
immunologically discriminate a 6pLOH(+) stem cell from a 6pLOH(−) stem cell 
(Supplementary Figure. 9A).  In particular, a 6pLOH(+) stem cell and a 6pLOH(−) 
 stem cell will produce the same number of progeny on average, and feed the same 
number of mature blood cells.  As a consequence, once established, the predominance 
of 6pLOH(+) stem cells over 6pLOH(−) stem cells should be maintained, after the 
severely reduced hematopoietic stem cell pool has been re-expanded with removal of 
the inciting autoimmunity.  It is also of note that the recovery of myeloid components 
after IST, which are affected more strongly by 6pLOH than lymphoid cells, contributes 
to an apparent increase in 6pLOH components in the SNP array analysis in PB 
(Supplementary Figure. 6A).  
One of the most significant findings in the current study is the identification of the 
HLA alleles that are overrepresented in the Japanese AA populations, including 
HLA-A*31:01, B*40:02, A*02:01, and A*02:06.  All of these HLA alleles belong to 
class I major histocompatibility complexes (MHCs) and thus are thought to be involved 
in the antigen presentation to CTLs.  This provides another prominent example, in 
which specific HLA-types play a critical role in the development of a human disease, 
and the information about these particular HLA types provides a solid basis on which 
we can ultimately isolate the relevant antigens responsible for the development of AA.  
Of particular note, there was a previous report that indicated that HLA-B*40:02 and 
A*02:06 were overrepresented in PNH as well as AA, although the study size was 
much smaller than the current study29.  Combined with our study, these findings 
support the hypothesis that AA and PNH are the different outcomes of the same 
immunologic insult5,30, and may also provide the genetic basis of the high prevalence of 
AA and PNH in East Asia31,32 
In some AA cases, hematopoiesis could be maintained over years by the progenitors 
that escaped and survived the inciting autoimmune insult by deleting the target HLA 
 through CNN-LOH in 6p.  Given that the 6pLOH was detected in only 13 % of our 
series, it is likely that other escape mechanisms may also operate to maintain 
hematopoiesis in AA.  In fact, clonality was clearly demonstrated in 20% of the 
6pLOH(−) cases in the HUMARA study (Supplementary Figure. 8).  In addition, our 
SNP array analysis also revealed a variety of clonal abnormalities in AA cases (Figure. 
1), although it is still open to question whether these abnormalities actually represent 
the mechanism of escape hematopoiesis or were related to some neoplastic process.  
Further studies on the genetic basis of the escape mechanisms would contribute to our 
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 Figure Legends 
Figure 1.  Copy number changes and allelic imbalances in 46 out of the 306 AA 
cases. 
The copy number changes and allelic imbalances (or CNN-LOHs) in each case are 
summarized in the chromosomal order vertically for 46 AA cases with copy number 
abnormalities. Gains and losses, as well as CNN-LOHs, are shown in the indicated 
colors. 
 
Figure 2.  Acquired 6pLOHs in AA patients that target the HLA locus. 
Panel A shows typical CNAG outputs in SNP array analysis showing CNN-LOH 
(purple line) that appears as significant dissociation in allele-specific copy number 
graphs (red and green lines) from the baseline with normal total copy numbers (tCN) 
(upper panel).  As a result of an allelic conversion, the affected segment causes LOH, 
where asterisks indicate one (lower panel). The “acquired” origin of these lesions is 
indicated by the retention of substantial numbers of heterozygous SNP calls (green bars 
below the chromatogram) that would otherwise mostly disappear.  Panel B 
summarizes the breakpoints of 6pLOHs found in a total of 28 AA cases, all involving 
the HLA locus in common.  In more than half of cases (indicated by arrowheads in 
Panel B), the exact location of the breakpoint was difficult to uniquely determine, 
where dissociation of the allele-specific copy number graphs continuously tapered 
along the 6p arm, indicating the presence of multiple 6pLOH(+) clones with common 
missing alleles (Panel C).  In fact, the breakpoint containing regions are separated into 
multiple segments having significantly different copy numbers in the circular binary 
 segmentation model, as indicated by solid lines with P-values.  Note that the most 
telomeric breakpoint is located within (case 24) or centromeric to (case 23) the HLA 
locus in each case.  Panel D shows a skewed distribution of the logarithm of p-values 
in AA cases compared with normal individuals. The p-values were calculated in the 
Mann-Whitney's U test, with which the difference in the mean allele-specific copy 
numbers between 6p and other chromosomal regions was evaluated (see Methods 
section).  >250 values are plotted as 250. 
 
Figure 3.  Uniparental expression of HLA in AA cases with CNN-LOH in 6p. 
Allele-specific expression of HLA-A antigens in AA specimens was examined by flow 
cytometry using monoclonal antibodies that specifically recognize the indicated HLA 
types (red lines), where leukocytes from healthy individuals were used as a control 
(blue lines).  Panels A and B show the uniparental expression of HLA-A antigens in 
PB leukocytes and BM CD34+ cells obtained from 3 AA cases with CNN-LOH in 6p.  
Different leukocyte compartments were separately examined, including granulocytes 
(G), monocytes (M), B-lymphocytes (B), and T-lymphocytes (T).  
 
Figure 4.  Imputation of missing HLA haplotypes.  
The observed allelic copy numbers at heterozygous SNP sites along each candidate 
SNP haplotype are color-coded as indicated at the bottom.  Green bars showed the 
SNPs that are incompatible with the patient's genotype.  Case IDs and haplotype ID 
(HT_ID) are indicated on the left.  The locations of the 500K SNPs and HLA-A, C, B, 
DRB1, DQB1, and DPB1 are indicated in the figure.  For each allele, genomic copy 
numbers were imputed using the circular binary segmentation algorithm.  This divided 
each haplotype into one or more segments having discrete mean allelic copy numbers 
 (blue arrows on the right).  The positions of breakpoints are indicated by arrowheads.  
Finally, the mean allelic copy number of each segment was statistically compared to 
that of corresponding segment on the other haplotype using the Wilcoxon signed rank 
test.  Missing HLA haplotypes were determined based on the result of the statistic 
tests.  Purple and Blue lines indicated the retained and missing segments, respectively, 
while the allelic status was not determined statistically for those segments shown by 
green lines. 
 
Figure 5.  A proposed mechanism for escape hematopoiesis in 6pLOH(+) AA. 
In AA, the targets of CTLs are the hematopoietic stem/progenitor (HSPC) cells that 
present some auto-antigen through particular Class I HLA molecules, including 
HLA-A*02:01, A*02:06, A*31:01, and B*40:02.  In the presence of these 
auto-immune insults, the HSPCs that lose their expression of the antigen-presenting 
HLA molecule as a result of CNN-LOH in 6p would acquire a growth advantage over 
other HSPCs expressing the relevant HLA, leading to clonal outgrowth of the 
6pLOH(+) progenies. 
  
 Table 1. Patients' characteristics     
  Newly diagnosed (n=107)  
Previously Treated 
(n=199) 
Age at diagnosis (months), median (range)     64 (9-88)     24 (2-80)  
Gender, Male/Female   58/49   110/89  
Severity of AA at onset, no. of patients (%)             
                 severe   79 (74%)   185 (93%)  
                 non severe     28 (26%)     14 (7%)  
History (months), median (range)   19 (0.1-251)   51 (0.1-372)  
Past treatment, no. of patients (%)             
          ATG+CsA   -   39 (20%)  
          CsA alone     -     51 (26%)  
          Anabolic steroid alone   -   13 (7%)  
          Unknown§     -     96 (48%)  
§Information regarding previous therapies of 96 cases (from Japan Marrow Donor Program) was 
unavailable.  
Abbreviations: ATG, antithymocyte globulin; CsA, cyclosporin A; PR, partial remission; CR, complete 
remission; -, not applicable.  
 
  




 MISSING ALLELES&  RETAINED ALLELES& 
 A B C DRB1 DQB1 DPB1  A B C DRB1 DQB1 DPB1 
19 53.9%  31:01* 40:02 03:04 12:01 03:01 05:01  24:02 52:01 12:02 15:02 06:01 05:01 
12 51.8%  02:01* 40:02 03:03 15:01 06:02 05:01  26:02 40:06 08:01 09:01 03:03 05:01 
17 51.6%  24:02 13:01 03:04 12:02 03:01 04:02  24:02 52:01 12:02 15:02 06:01 09:01 
304 49.3%  31:01* 55:02 01:02 12:02 03:01 41:01  24:02 07:02 07:02 01:01 05:01 04:02 
11 48.0%  02:06* 40:02 03:04 15:01 06:02 ND§1  11:01 67:01 07:02 16:02 05:02 ND§1 
21 46.2%  31:01* 51:01 14:02 14:05 05:03 03:01  24:02 07:02 07:02 01:01 05:01 04:02 
24 44.9%  31:01 40:02 03:04 11:01 03:01 02:01  24:02 40:06 08:01 09:01 03:03 05:01 
26 44.3%  31:01*♮ 40:01 03:04 04:05 04:01 03:01  26:03 52:01 12:02 15:02 06:01 09:01 
27 43.5%  02:06 40:02 03:04 04:10 04:02 02:01  11:01 52:01 12:02 15:02 06:01 09:01 
10 42.1%  31:01 40:02 03:04 08:03 06:01 02:01  24:02 51:01 14:02 09:01 03:03 02:01 
8 40.8%  02:06* 40:02 03:03 12:01 03:01 05:01  24:02 52:01 12:02 15:02 06:01 04:02 
23 35.2%  02:01 40:02 03:04 09:01 03:03 02:01  24:02 54:01 01:02 04:05 04:01 04:02 
25 32.1%  02:06* no LOH  01:01 no LOH 
9 23.5%  02:06* 39:01 07:02 08:02 04:02 02:01  24:02 15:18 07:04 04:01 03:01 14:01 
20 21.7%  26:01* 40:02 03:03 15:01 06:02 05:01  02:18 46:01 01:02 08:03 06:01 05:01 
14 21.7%  31:01* 51:01 14:02 09:01 03:03 05:01  24:02 52:01 12:02 15:02 06:01 09:01 
22 20.6%  02:01 39:01 07:02 08:03 06:01 05:01  24:02 52:01 12:02 15:02 06:01 09:01 
18 17.6%  02:01* 40:06 08:01 09:01 03:03 02:01  24:02 35:01 03:03 15:01 06:02 04:02 
15 17.4%  02:06 40:06 08:01 09:01 03:03 02:01  24:02 07:02 07:02 01:01 05:01 02:01 
41 15.2%‡  31:01* 35:01 03:03 09:01 03:03 03:01  26:01 39:01 07:02 08:03 06:01 05:01 
28 12.8%  24:02 54:01 01:02 01:01 05:01 04:02  24:02 52:01 12:02 15:02 06:01 09:01 
29 11.7%  31:01 40:02 03:04 15:01 06:02 02:01  24:02 54:01 01:02 04:05 04:01 05:01 
305 10.3%  02:06* 40:02 15:02 15:02 06:01 04:01  24:02 51:01 14:02 09:01 03:03 02:01 
13 9.6%  24:02* 40:02 03:04 15:01 06:02 02:01  02:01 35:01 08:01 09:01 03:03 02:01 
306 8.5%  24:02* 40:02 03:04 09:01 03:03 02:01  26:02 40:06 08:01 09:01 03:03 02:01 
16 8.1%  11:01 40:06 08:01 no LOH  24:02 46:01 01:02 no LOH 
30 8.0%  02:06 39:01 07:02 no LOH  24:02 40:06 08:01 no LOH 
72 5.6%  02:01 40:02 03:04 09:01 03:03 05:01  02:07 46:01 01:02 08:03 06:01 02:02 
36 4.0%  02:01* ND§2 ND§3 15:02 06:01 09:01  24:02 ND§2 ND§3 15:02 06:01 09:01 
124 3.5%  24:02 40:02 03:04 12:01 03:01 02:01  24:02 52:01 12:02 15:02 06:01 09:01 
223 2.8%  31:01* 48:01 03:04 09:01 03:03 05:01  02:06 39:01 07:02 15:01 06:02 02:01 
215 2.8%  31:01 51:01 14:02 08:02 04:02 04:02  03:01 44:02 05:01 13:01 06:03 05:01 
181 1.3%  02:06 13:01 03:04 12:02 03:01 05:01  24:02 52:01 12:02 15:02 06:01 09:01 
97 1.0%  24:02 07:02 07:02 01:01 05:01 05:01  02:01 39:01 07:02 15:01 06:02 02:01 
252 0.9%  ND§4 40:02 03:04 09:01 03:03 05:01  ND§4 46:01 01:02 04:05 04:01 05:01 
118 0.9%  02:06* 40:02 03:04 08:02 03:02 05:01  24:02 52:01 12:02 15:02 06:01 09:01 
298 0.8%  24:02 40:02 03:04 15:01 06:02 05:01  24:02 52:01 12:02 15:02 06:01 09:01 
188 0.7%  24:02 52:01 12:02 15:02 06:01 09:01  02:01 52:01 12:02 11:01 03:01 05:01 
291 0.7%  31:01 51:01 14:02 15:01 06:02 02:01  24:02 40:01 03:04 11:01 03:01 05:01 
196 0.2%  ND§5 (A*02:06/24:02, B*35:01/51:01, C*03:03/15:02, DRB1*04:03/15:01, DQB1*03:02/06:02, DPB1*0:201/02:01) 
※The percentage of 6pUPD(+) fraction is derived from total peripheral blood leukocytes that include lymphoid as well as myeloid element. 
* The allelic loss was confirmed by FCM. 
& HLA types significantly deviated to missing alleles are indicated by shadows. 
§1: DPB1*04:02/05:01, §2: B*15:18/52:01, §3: C*08:01/12:02, §4; A*02:01/02:07, §5; Missing allele was not determined because copy number 
changes in these segments were not statistically significant. 
♮ The missing haplotype was determined by flow cytometry. 
 
  
 Table 3. Response rate (CR+PR) according to the Camitta criteria 
 Newly diagnosed                (n=107)  
Previously treated              
(n=103) 







Immunosuppressive therapies (all)  36/49 (73%)  11/11 (100%)    65/77 (84%)  12/12 (100%)  
          ATG+CsA  14/19 (74%)  7/7 (100%)   27/33 (82%)  5/5 (100%)  
          CsA alone  22/30 (73%)  4/4 (100%)    38/44 (86%)  7/7 (100%)  
Anabolic steroid alone  0/0 (0%)  0/0 (0%)    7/11 (64%)  2/2 (100%)  
Unknown/Not evaluable  42 5   0 1 







Table 4. Association of missing HLA alleles with AA in Japanese patients 
Risk allele AA Other diseases Total P-value Odds Ratio ( 95% CI )   ( N=407 ) ( N=6206 ) ( N=6613 ) (χ2 test) (vs. no risk alleles) 
A*02:01 103 1173 1276 2.5 x 10-6 1.87 ( 1.43  − 2.43  ) 
A*02:06 100 957 1057 < 1.0 x 10-7 2.22 ( 1.70  − 2.90  ) 
A*31:01 58 899 957 0.048  1.37 ( 1.00  − 1.88  ) 
B*40:02 86 938 1024 1.8 x 10-6 1.95 ( 1.48  − 2.58  ) 
All risk alleles 268 3250 3518 1.3 x 10-7 1.75  ( 1.42  − 2.17  ) 
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